市場調查報告書
商品編碼
1546284
心電圖掃描器(ECG)的全球市場的評估:各類型,各技術,各導線類型,各終端用戶,各地區,機會,預測(2017年~2031年)Electrocardiograph (ECG) Market Assessment, By Type, By Technology, By Lead Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球心電圖機 (ECG) 市場規模預計將從 2023 年的 84.019 億美元增至 2031 年的 152.3169 億美元,複合年增長率預計為 7.72%。由於心臟病的增加,該市場正在穩步增長,預計未來將繼續大幅增長。
心電圖機是一種用於記錄心跳並分析可能的心血管問題的設備和技術。隨著心血管疾病負擔的增加,對心電圖檢查和新設備的需求也增加。心電圖設備市場預計將在設計和功能方面的技術進步、人工智慧和設備學習的整合以及用於心電圖記錄的可穿戴設備的成長趨勢等因素的影響下成長。政府透過提供足夠的醫療設備來加強醫療基礎設施的努力正在推動市場的成長。此外,不斷增加的投資和將技術整合到心電圖設備中的新興新創公司正在推動市場成長。
例如,2024 年 4 月,班加羅爾健康科技新創公司 Tricog Health India Pvt Ltd. 在 B2 輪融資中籌集了 850 萬美元,投資者包括 OMRON Healthcare India Pvt Ltd. 和 Sony Innovation Fund I。該公司利用人工智慧分析心電圖/心電圖和迴聲掃描來診斷心臟異常,這筆資金將進一步開發利用人工智慧的心臟護理解決方案。然而,儘管存在多種驅動因素??,但諸如大量本地參與者的市場飽和以及各國不同的嚴格監管程序等挑戰是市場成長的主要障礙。
心血管疾病盛行率增加
全世界心血管疾病負擔的增加是心電圖設備和相關診斷技術需求和採用增加的主要驅動力,這些設備和技術能夠實現這些疾病的早期檢測和管理。由於心血管疾病主要透過心電圖技術診斷,心血管疾病負擔的增加將增加對心電圖設備和服務的需求。致力於心血管健康的各種組織,包括美國心臟協會、英國心臟基金會和世界衛生組織,一致報告心血管疾病顯著增加。例如,2024 年 6 月,兩項新的美國心臟協會主席建議報告預測,超過 1.84 億人(占美國人口的 61% 以上)將患有某種形式的心血管疾病 (CVD) 和總 CVD。 2050 年,相關成本預計將增加兩倍,達到1.8 兆美元。
科技進步推動市場成長
與醫療技術的其他領域一樣,心電圖設備也顯示出多項技術進步。最近的技術進步包括穿戴式心電圖設備(例如美國 FDA 批准的 Apple Watch Series 4)、人工智慧輔助心電圖解讀、便攜式心電圖監視器、非接觸式監護系統、基於雲端的系統以及與遠距醫療的整合。這些進步旨在提高心臟病的診斷準確性並提高數據收集和分析的效率。人工智慧與心電圖的整合預計將帶來巨大的改進,並使患者更容易獲得心電圖服務,從而帶來後續的市場擴張。例如,2024 年 5 月,OMRON Healthcare India Pvt Ltd 宣布與 AliveCor India(AliveCor 的子公司)建立合作夥伴關係。透過此次合作,除了血壓監測產品外,歐姆龍還將提供基於人工智慧的手持式便攜式心電圖技術。該合作夥伴關係將創建一種可以檢測包括心房顫動在內的各種心律不整的設備,並提供心血管疾病的早期檢測和管理。該協議旨在提高人們的認識並預防心血管健康,特別是在印度等高血壓和心電圖監測方面差異很大的國家。
本報告提供全球心電圖掃描器(ECG)市場相關調查分析,提供市場規模與預測,市場動態,主要企業的形勢及預測等資訊。
Global electrocardiograph (ECG) market is projected to witness a CAGR of 7.72% during the forecast period 2024-2031, growing from USD 8401.90 million in 2023 to USD 15231.69 million in 2031. The market for ECG devices is rising consistently due to increasing cardiac diseases and is anticipated to keep growing at a significant rate.
An electrocardiograph is a device and technique used to record the heartbeat and analyze any possible cardiovascular disorder. As the burden of cardiovascular diseases increases, the demand for more ECG procedures and new devices subsequently rises. The market for ECG devices is anticipated to thrive under the influence of factors like technical advancements in design and functions, integration of artificial intelligence (AI) and machine learning, the growing trend of wearable devices for recording ECG, etc. The government initiatives to strengthen the healthcare infrastructure by establishing an adequate number of medical devices drive the growth in the market. Additionally, rising investments and emerging startups integrating technology in ECG devices are boosting the market growth.
For instance, in April 2024, Tricog Health India Pvt Ltd., a Bengaluru-based health tech startup, raised USD 8.5 million in a Series B2 funding round from investors including OMRON Healthcare India Pvt Ltd and Sony Innovation Fund. The company uses AI to analyze ECG/EKG and ECHO scans to diagnose heart anomalies, and the new funding will help it further develop its AI-powered cardiac care solutions. However, despite several driving forces, challenges like saturation in the market due to the large number of local players, and stringent regulatory procedures varying from country to country pose significant hindrances to market growth.
Rising Prevalence of Cardiovascular Diseases
The rising burden of cardiovascular diseases globally is a key factor fueling increased demand and adoption of ECG machines and related diagnostic technologies to enable earlier detection and management of these conditions. Cardiovascular diseases are mainly diagnosed with ECG technology, which implies that an increase in cardiovascular disease burden will enhance the demand for ECG devices and services. Various associations working for cardiovascular health, such as the American Heart Association, the British Heart Foundation, and WHO, are consistently reporting a significant rise in cardiac diseases. For instance, in June 2024, as per the projections reported in two new American Heart Association presidential advisories, more than 184 million people, exceeding 61% of the U.S. population, are likely to have some type of cardiovascular disease (CVD) and total CVD-related costs are expected to triple to USD 1.8 trillion by 2050.
Technological Advancements Drive Market Growth
Aligning with other domains of medical technology, ECG devices are also undergoing several technical advancements. Some of the recent technical advancements include wearable ECG devices (for example, U.S. FDA-approved Apple Watch Series 4), AI-assisted ECG interpretation, portable ECG monitors, contactless monitoring systems, cloud-based systems, integration with telemedicine, and many more. These advances aim to improve accuracy in the diagnosis of heart conditions and enhance the efficiency of data collection and analysis. AI integration in ECG is anticipated to result in drastic improvements, leading to easy patient access to ECG services and subsequent market expansion. For instance, in May 2024, OMRON Healthcare India Pvt Ltd announced a collaboration with AliveCor India (a subsidiary of AliveCor, Inc.). Through this partnership, OMRON will now offer AI-based handheld portable ECG technology in addition to its blood pressure monitoring products. The collaboration will result in devices that can detect various heart arrhythmias, including atrial fibrillation, and provide early cardiovascular disease detection and management. The deal aims to enhance cardiovascular health awareness and prevent incidents, especially in a country like India, where hypertension and ECG monitoring gaps are significant.
Devices Segment Dominates the Global (ECG) Market
ECG device installations are increasing with the expanding healthcare infrastructure. With the rising burden of cardiac diseases and subsequent demand for more ECG procedures and devices, the ECG device segment is anticipated to cover a major market share. Technical advancements and device upgrades in diagnostic centers and hospitals further catalyze the increasing market share of the devices segment. For example, in January 2024, Wellysis Corp. launched its revolutionary electrocardiogram (ECG) monitoring solution, 'S-Patch,' into the lucrative United States and Indian markets. The company has secured a strategic supply agreement with a leading provider of ECG services in the United States, initially deploying 1,000 devices across Texas, Arizona, and Louisiana, with a two-year supply commitment. Additionally, Wellysis has partnered with Turtle Shell Technologies Private Limited (Dozee), a prominent bed monitoring solutions provider in India, to integrate and supply 50,000 S-Patch devices to hospital beds starting in January.
North America Dominates Electrocardiograph (ECG) Market Share
North America is anticipated to dominate the ECG market. North America, particularly the United States, has a significant demand for ECG devices due to several key factors. The high prevalence of cardiovascular diseases, an aging population, and a well-developed healthcare infrastructure with robust reimbursement policies have all contributed to this demand. Sustained efforts by healthcare organizations like the U.S. FDA to raise awareness about heart health and product approvals are also driving the demand for these diagnostic and monitoring tools in North America. For instance, in June 2024, Tempus AI, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device, an AI-based algorithm designed to identify patients at increased risk of atrial fibrillation (AF). This innovative technology uses machine learning to analyze 12-lead electrocardiogram (ECG) recordings, helping clinicians detect signs of AF within the next 12 months. The device is intended for use on resting ECG recordings from patients aged 65 and older without a known history of AF.
Future Market Scenario (2024-2031F)
ECG technology plays a pivotal role in the cardiology domain, and with growing advancements, the machinery for recording ECG has changed drastically in recent years. The evolving trend of wearable devices has greatly impacted ECG monitoring as well. Nowadays, several smartwatches and other kinds of wearable devices are available in the market that can easily record patients' ECGs. This is anticipated to revolutionize the ECG market in upcoming years. Market players are also actively developing wearable devices to cater to the rising demand. For instance, in September 2023, iRhythm Technologies, Inc. launched its next-generation Zio monitor. This prescription-only ECG monitoring device is part of the company's Zio long-term continuous monitoring (LTCM) service. The new Zio monitor is 23% thinner, 62% lighter, and 72% smaller than its predecessor, enhancing patient comfort and adherence. It features a waterproof design and requires no device or adhesive manipulation during the 14-day wear period.
Key Players Landscape and Outlook
GE HealthCare Technologies, Inc., Koninklijke Philips N.V., Hill-Rom Holdings, Inc., NIHON KOHDEN CORPORATION, Fukuda Denshi Co Ltd, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Schiller AG, Spacelabs Healthcare, Inc., BPL MEDICAL TECHNOLOGIES PRIVATE LIMITED, Allengers Medical Systems Ltd are some of the leading players in the ECG market. The market witnessed some substantial market deals like mergers and collaborations to expand the market share of key players.
In February 2024, Thyrocare Technologies Ltd., a leading diagnostic service provider, acquired Chennai-based Think Health Diagnostics Pvt Ltd to expand its presence in the pre-policy medical check-up segment for the insurance market by offering both blood tests and ECGs as a one-stop solution, leveraging Think Health's operational presence in 10 cities and Thyrocare's network of over 900 blood collection phlebotomists trained to provide ECGs at home, aiming to expand these services to more than 100 cities in the next year and deliver seamless healthcare directly to patient's doorsteps.
In May 2024, WearLinq, Inc. acquired AMI Cardiac Monitoring LLC, which is an independent diagnostic testing facility with over 33 years of expertise in ambulatory cardiac monitoring. This strategic acquisition will expand WearLinq's clinical services across all 50 U.S. states and provide more patients access to its FDA-cleared 6-lead wearable ECG monitor, the eWave. The combined capabilities of AMI's clinical expertise and WearLinq's advanced technology are expected to revolutionize the field of ambulatory cardiac monitoring, enabling more accurate diagnoses and improved patient outcomes.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.